Drug addiction: from bench to bedside
Open accessAbstract
Drug addiction is responsible for millions of deaths per year around the world. Still, its management as a chronic disease is shadowed by misconceptions from the general public. Indeed, drug consumers are often labelled as “weak”, “immoral” or “depraved”. Consequently, drug addiction is often perceived as an individual problem and not societal. In technical terms, drug addiction is defined as a chronic, relapsing disease resulting from sustained effects of drugs on the brain. Through a better characterisation of the cerebral circuits involved, and the long-term modifications of the brain induced by addictive drugs administrations, first, we might be able to change the way the general public see the patient who is suffering from drug addiction, and second, we might be able to find new treatments to normalise the altered brain homeostasis. In this review, we synthetise the contribution of fundamental research to the understanding drug addiction and its contribution to potential novel therapeutics. Mostly based on drug-induced modifications of synaptic plasticity and epigenetic mechanisms (and their behavioural correlates) and after demonstration of their reversibility, we tried to highlight promising therapeutics. We also underline the specific temporal dynamics and psychosocial aspects of this complex psychiatric disease adding parameters to be considered in clinical trials and paving the way to test new therapeutic venues.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Case reports and small case studies targeting the nucleus accumbens for the treatment of alcohol use disorder and opioid use disorder have shown promising results, but much more research is needed.
“Case reports and small case studies targeting the nucleus accumbens for the treat ment of alcohol use disorder and opioid use disorder have shown promising results 215 , but much more research is needed.”
From Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention (2023) · cites this paper as [215]
At present, the only FDA-approved SUD-related indications for neuromodulation are transcranial magnetic stimulation for smoking cessation, and percutaneous nerve field stimulation for treatment of opioid withdrawal.
“At present, the only FDA- approved SUD- related indications for neuromodulation are transcranial magnetic stimulation for smok ing cessation 216 , and percutaneous nerve field stimulation for treat ment of opioid withdrawal 215 .”
From Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention (2023) · cites this paper as [215]
The Clinical treatments for drug addiction section discusses rTMS as a potential addiction treatment, and the References list a study of rTMS for cigarette craving and consumption. Neither passage establishes FDA approval. Searches for FDA-approved neuromodulation and percutaneous nerve field stimulation found no passage addressing the claimed approvals or their exclusivity; page numbers were unavailable in our copy. (LLM, conf=0.74)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 260 · Cited by 75
Research works printed but not linked: 1
- [252]Piazza PV Deroche-Gamonet V A multistep general theory of transition to addiction Psychopharmacology 2013 229 387 413 10.1007/s00213-013-3224-4 23963530 PMC3767888 · DOI · Paper page
- Authors
- Cheron, J., & Kerchove d’Exaerde, A. D.
- Venue
- Translational Psychiatry
- Published
- 2021-08-12
- Volume
- 11
- Issue
- 1
- Pages
- 424-424
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC8361217
- OpenAlex
- W3189451169
- Cited by
- 75
- References
- 260
- Citations by year
- 2026: 7 · 2025: 28 · 2024: 19 · 2023: 14 · 2022: 5 · 2021: 2
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Translational Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FRS/FNRS (Belgium) Fondation Simone et Pierre Clerdent (Belgium) Fondation ULB Université Libre de Bruxelles
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- drug addiction, chronic relapsing disease, brain circuits, synaptic plasticity, epigenetic mechanisms, stigma, public perception of addiction, psychosocial aspects, temporal dynamics, clinical trials
- MeSH terms
- Brain, Humans, Neuronal Plasticity, Behavior, Addictive, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review